ClinicalTrials.gg
CompletedNCT05759624VESCIGHTPUpdated Nov 10, 2026

Vesiculogenesis in Children With GH Deficiency (VESCIGHTP)

An observational study in GH Deficiency, sponsored by Istituto Auxologico Italiano. Completed at 1 site in Italy. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

Updated Nov 10, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
5 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Dwarfism, Pituitary with a site in Italy — 2 open to participants now, 2 under way, none of them phase 3. Dwarfism, Pituitary · Italy.

Started
2022
the only one that year
Observational
8 of 28
1 open now
Registered
25th of 28
by date
Lead sponsor
2 of 28
Istituto Auxologico Italiano

Among the 28 studies in Dwarfism, Pituitary with a site in Italy, this one is the only one that started in 2022, is one of 8 observational ones, and was the 25th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

2 of the 28 studies in Dwarfism, Pituitary with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Dwarfism, Pituitary with a site in Italy, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the size and derivational profile of the extracellular vescicles (EV) generated in children with GH deficiency, undergoing hormone replacement therapy with rhGH. Secondary objectives is to correlate vesiculogenesis with auxometric and biochemical parameters used in clinical-endocrine practice in the evaluation of short stature.

The results of the study will provide useful information to more rationally set up the clinical and biochemical follow-up of hormone replacement therapy with rhGH, as well as to understand the molecular and cellular mechanisms underlying the multi-systemic action of GH, the most important anabolic hormone of the human organism.

Read the detailed description

Methods:

At the Regional Reference Center for Growth Disorders, Istituto Auxologico Italiano, IRCCS, Milan, 10 children of both sexes affected by isolated GH deficiency will be recruited according to the criteria set out in AIFA note 39 for this pathology (short stature: ≤ - 3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different stimulating pharmacological tests \< 8 ng/ml). The exclusion criterion from the present study (and from treatment with rhGH) will be the presence of organic pathologies at the hypothalamic-pituitary level (assessed by brain MRI).

In basal conditions (pre-treatment), we will proceed with the collection of clinical and anthropometric/auxometric data, including the evaluation of body composition with bioimpedance analysis. The same work-up will be repeated at the subsequent 6-month follow-up (see below).

Each subject will undergo hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).

In conditions of fasting (at least 12 hours), blood samples will be taken at T0 (i.e., before the start of hormone replacement therapy with rhGH) and at T6 (i.e., after 6 months of rhGH, approximately 10-12 hours after administration of the previous day's dose).

In the samples taken at T0 and T6, the dimensional and derivational profiles of the EVs will be determined. Markers for the following cell subtypes will be identified: endothelium (activated and not), monocytes, neutrophils, platelets, muscle, bone, and adipose tissue.

In basal conditions (T0) and at T6 the patients will be sampled for the determination of the following parameters: complete blood count + formula, blood glucose, insulin, glycated Hb, triglycerides, total cholesterol, LDL, HDL, hsPCR, IGF-1, osteocalcin, ICTP, and PIIIINP.

Quantitative data will be expressed as mean ± SD or as median with interquartile range (Q1-Q3), as appropriate. Categorical data will be presented as frequencies and percentages, while continuous variables will be tested for normality and linearity. If appropriate, a log transformation of the data will be performed. The paired Student's t-test (or other non-parametric test) will be used to compare demographic, clinical, and biochemical characteristics among the same subjects at T0 vs. T6. EVs will be subdivided according to their size (exosomes, microvesicles, and total EVs) and their cellular origin identified by specific markers (e.g., CD14+, CD61+, CD62E+, CD105+, SCGA+, FABP+, etc). Multiple linear regression analysis will be applied to evaluate the association between EVs (as Δ% between T0 and T6 for the dimensional and also derivational profile), circulating IGF-1 levels (as Δ% between T0 and T6), and the rate of growth (T0 to T6). In addition, a paired Student t-test will be used to assess the rhGH-induced change in EV (T0 vs. T6). The test will be applied for all EV populations studied with the size profile and for all vesicular markers studied with the derivational profile. Alternatively, a non-parametric test will be applied. A p-value \< 0.05 will be considered.

03

Conditions studied

  • GH Deficiency

Keywords

  • Growth
  • GH deficiency
  • Children
  • Short stature
  • Extracellular vescicles
04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

10 children of both sexes affected by isolated GH deficiency will be recruited according to the criteria set out in AIFA note 39 for this pathology (short stature: ≤ - 3 SD or ≤ -2 SD and growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart and peak GH at two different stimulus pharmacological tests \< 8 ng/ml).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • short stature: ≤ - 3 SD or ≤ -2 SD
  • growth velocity/year ≤ -1.0 SD for age and sex evaluated at least 6 months apart - peak GH at two different stimulus pharmacological tests \< 8 ng/ml

Exclusion criteria

Exclusion Criteria:

- presence of organic pathologies at the hypothalamic-pituitary level (assessed by performing brain MRI).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Hormone replacement therapy with rhGH

    Drug: rhGH

Interventions

06

What researchers measure

Primary outcomes

  1. Size of extracellular vesicles

    Change in size of extracellular vesicles after rhGH treatment

    Time frame: Baseline and after 6 months

  2. Derivational profile of extracellular vesicles

    Change in derivational profile of extracellular vesicles after rhGH treatment

    Time frame: Baseline and after 6 months

Secondary outcomes

  1. Auxometric parameters - height

    Change in height after rhGH treatment

    Time frame: Baseline and after 6 months

  2. Auxometric parameters - weight

    Change in weight after rhGH treatment

    Time frame: Baseline and after 6 months

  3. Biochemical parameters - glycemia

    Change in glycemia after rhGH treatment

    Time frame: Baseline and after 6 months

  4. Biochemical parameters - Insulin-like growth factor I (IGF-I)

    Change in IGF-I after rhGH treatment

    Time frame: Baseline and after 6 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2026, 45 months.

Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's 45 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Mar 2026 and completion Dec 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2023
First posted
Mar 8, 2023
StartActual
Jun 24, 2022
Primary completionActual
Mar 26, 2026was Dec 2025
CompletionActual
Mar 26, 2026was Dec 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 31, 2025→Mar 26, 2026 (actual)
Nov 10, 2026
Study completion
Dec 31, 2025→Mar 26, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2025→Mar 26, 2026 (now actual)
    Study completion Dec 31, 2025→Mar 26, 2026 (now actual)
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05759624
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Jun 24, 2022
Primary completion
Mar 26, 2026
Completion
Mar 26, 2026
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion